Drug
Biosimilar Infliximab
Biosimilar Infliximab is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
1
25%
Ph phase_3
1
25%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (50.0%)
Phase 41 (50.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
BackToBasic: Infliximab in Chronic Low Back Pain and Modic Changes
NCT03704363
completed
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
NCT02728934
completed
Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan
NCT03348046
completedphase_4
The NOR-SWITCH Study
NCT02148640
Clinical Trials (4)
Showing 4 of 4 trials
NCT03704363Phase 3
BackToBasic: Infliximab in Chronic Low Back Pain and Modic Changes
NCT02728934
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
NCT03348046
Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan
NCT02148640Phase 4
The NOR-SWITCH Study
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4